Welcome to our dedicated page for Moolec Science SA SEC filings (Ticker: MLECW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Moolec Science SA’s warrants (MLECW) provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents cover the activities of Moolec Science, a science-based ingredient company focused on producing animal proteins in plants through Molecular Farming, and offer detailed insight into its corporate structure, transactions, and financial reporting.
Investors can review Form 20-F annual reports for audited consolidated financial statements of Moolec Science SA, along with discussions of its Molecular Farming technology, alternative protein ingredient focus, and risk factors. Interim information is available through Form 6-K filings, which Moolec uses to furnish unaudited financial statements, pro forma financial information, and updates on significant corporate events.
A notable Form 6-K describes a ten-to-one reverse stock split of Moolec Science (Luxembourg) ordinary shares and the subsequent redomiciliation to the Cayman Islands, where the company continues as Moolec Science (Cayman Islands). The same filing explains a business combination agreement with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, under which Moolec became the legal parent of the combined group while Bioceres Group Limited is treated as the accounting acquirer under IFRS 3.
That Form 6-K also discusses changes in control at Bioceres Crop Solutions Corp., debt defaults and restructuring processes at Bioceres S.A. and Bioceres LLC, and states that these events raise a material uncertainty that may cast significant doubt about the ability of the Bioceres Group and Moolec Science to continue as a going concern. The filing notes that the consolidated financial statements do not include adjustments that might result from this uncertainty.
On this page, Stock Titan pairs these filings with AI-powered summaries that explain the key points of lengthy documents such as 20-F annual reports and 6-K current reports. Users can quickly understand reverse stock split mechanics, jurisdiction changes, business combinations, and going concern disclosures without reading every page. Real-time updates from EDGAR ensure that new Moolec Science filings, including those related to the MLECW warrants, appear promptly with concise explanations to support investor research.
Moolec Science SA completed corporate restructuring and a major acquisition combining several agtech entities while disclosing significant financing stress.
The company implemented a 10-for-1 reverse stock split and redomiciled from Luxembourg to the Cayman Islands, with fractional shares rounded up and all per-share data adjusted for the Consolidation Ratio. On June 16, 2025 Moolec closed a Business Combination that made it legal parent of Bioceres Group, Gentle Tech and Nutrecon; the EGM had 77% attendance and the transaction received 98% of votes cast. IFRS 3 treats Bioceres Group Limited as the accounting acquirer.
Post-closing amendments to secured notes for Bioceres Crop Solutions led to loss of de facto control and deconsolidation; the leverage covenant was revised to 5x and maturity extended to August 31, 2027. Bioceres S.A. initiated a debt restructuring for $36.4 million and Bioceres LLC received a $69.5 million default notice and auction of 3,062,500 pledged BIOX shares. Management cites a material uncertainty about the Group’s ability to continue as a going concern and describes plans to restructure debt, seek investor financing and operate a Restructuring Committee.
FAQ
What is the current stock price of Moolec Science SA (MLECW)?
